| A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy (NCT07752264) | Nanjing IASO Biotechnology Co., Ltd. | 2026-08-15 |
| Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (NCT07510100) | Nanjing IASO Biotechnology Co., Ltd. | 2026-05-10 |
| UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis (NCT07109986) | Nanjing IASO Biotechnology Co., Ltd. | 2025-10-27 |
| Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis (NCT07055724) | Nanjing IASO Biotechnology Co., Ltd. | 2025-07-01 |
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies (NCT06743503) | Nanjing IASO Biotechnology Co., Ltd. | 2025-04-11 |
| Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection (NCT07028970) | Nanjing IASO Biotechnology Co., Ltd. | 2024-12-15 |
| A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) (NCT06464991) | Nanjing IASO Biotechnology Co., Ltd. | 2024-03-27 |
| A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (NCT05698303) | Nanjing IASO Biotechnology Co., Ltd. | 2023-05-08 |
| A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT05759793) | Nanjing IASO Biotechnology Co., Ltd. | 2023-03-30 |
| A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) (NCT05181501) | Nanjing IASO Biotechnology Co., Ltd. | 2022-04-01 |
| A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT05091541) | Nanjing IASO Biotechnology Co., Ltd. | 2021-10-20 |
| A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (NCT05066646) | Nanjing IASO Biotechnology Co., Ltd. | 2020-04-01 |